Completed PHASE3 INTERVENTIONAL 3-arm NCT00596271

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study

Sponsor: Valneva Austria GmbH

Conditions Japanese Encephalitis

Interventions HAVRIX IC51 Placebo

Updated 8 times since 2017 Last updated: Apr 9, 2014 Started: Sep 30, 2005 Primary completion: Jul 31, 2006 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Japanese Encephalitis and is currently completed. Valneva Austria GmbH leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Valneva Austria GmbH

Data source: Valneva Austria GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.